全科医学临床与教育
全科醫學臨床與教育
전과의학림상여교육
CLINICAL EDUCATION OF GENERAL PRACTICE
2014年
4期
374-376
,共3页
人乳头瘤病毒L1壳蛋白%宫颈上皮内瘤变%高危型人乳头瘤病毒
人乳頭瘤病毒L1殼蛋白%宮頸上皮內瘤變%高危型人乳頭瘤病毒
인유두류병독L1각단백%궁경상피내류변%고위형인유두류병독
human papillomavirus-L1 capsid protein%cervical intraepithelial neoplasia%high-risk human papillo-mavirus
目的探讨宫颈上皮内瘤变（CIN）患者治疗前人乳头瘤病毒（HPV）-L1壳蛋白的表达能否成为预测治疗后疾病转归的指标。方法通过免疫组化法检测CIN患者治疗前HPV-L1壳蛋白表达，把CIN患者分为两组：CINⅠ级组、CINⅡ~Ⅲ级组。治疗后12个月通过导流杂交基因芯片技术检测高危型人乳头瘤病毒（HR-HPV）DNA的表达。结果治疗前CINⅠ的涂片中HPV-L1壳蛋白阳性表达率为75.00％，CINⅡ~Ⅲ的涂片中HPV-L1壳蛋白阳性表达率为36.13％，两者比较差异有统计学意义（χ2=15.43，P＜0.05）。CINⅠ级组：术前HPV-L1壳蛋白阳性的患者在术后12个月随访过程中，HR-HPV持续感染阳性率为0％，而术前HPV-L1壳蛋白阴性的患者，术后HR-HPV持续感染阳性率为25.00％。两者比较差异有统计学意义（χ2=6.40，P＜0.05）；CINⅡ~Ⅲ级组：术前HPV-L1壳蛋白阳性的患者，术后12个月随访过程中，HR-HPV持续感染阳性率为2.33％；而术前HPV-L1壳蛋白阴性的患者，术后HR-HPV持续感染阳性率为22.37％。两者比较差异有统计学意义（χ2=6.44，P＜0.05）。结论 CIN患者治疗前HPV-L1壳蛋白的检测有可能成为评估CIN患者治疗后预测疾病转归的指标。
目的探討宮頸上皮內瘤變（CIN）患者治療前人乳頭瘤病毒（HPV）-L1殼蛋白的錶達能否成為預測治療後疾病轉歸的指標。方法通過免疫組化法檢測CIN患者治療前HPV-L1殼蛋白錶達，把CIN患者分為兩組：CINⅠ級組、CINⅡ~Ⅲ級組。治療後12箇月通過導流雜交基因芯片技術檢測高危型人乳頭瘤病毒（HR-HPV）DNA的錶達。結果治療前CINⅠ的塗片中HPV-L1殼蛋白暘性錶達率為75.00％，CINⅡ~Ⅲ的塗片中HPV-L1殼蛋白暘性錶達率為36.13％，兩者比較差異有統計學意義（χ2=15.43，P＜0.05）。CINⅠ級組：術前HPV-L1殼蛋白暘性的患者在術後12箇月隨訪過程中，HR-HPV持續感染暘性率為0％，而術前HPV-L1殼蛋白陰性的患者，術後HR-HPV持續感染暘性率為25.00％。兩者比較差異有統計學意義（χ2=6.40，P＜0.05）；CINⅡ~Ⅲ級組：術前HPV-L1殼蛋白暘性的患者，術後12箇月隨訪過程中，HR-HPV持續感染暘性率為2.33％；而術前HPV-L1殼蛋白陰性的患者，術後HR-HPV持續感染暘性率為22.37％。兩者比較差異有統計學意義（χ2=6.44，P＜0.05）。結論 CIN患者治療前HPV-L1殼蛋白的檢測有可能成為評估CIN患者治療後預測疾病轉歸的指標。
목적탐토궁경상피내류변（CIN）환자치료전인유두류병독（HPV）-L1각단백적표체능부성위예측치료후질병전귀적지표。방법통과면역조화법검측CIN환자치료전HPV-L1각단백표체，파CIN환자분위량조：CINⅠ급조、CINⅡ~Ⅲ급조。치료후12개월통과도류잡교기인심편기술검측고위형인유두류병독（HR-HPV）DNA적표체。결과치료전CINⅠ적도편중HPV-L1각단백양성표체솔위75.00％，CINⅡ~Ⅲ적도편중HPV-L1각단백양성표체솔위36.13％，량자비교차이유통계학의의（χ2=15.43，P＜0.05）。CINⅠ급조：술전HPV-L1각단백양성적환자재술후12개월수방과정중，HR-HPV지속감염양성솔위0％，이술전HPV-L1각단백음성적환자，술후HR-HPV지속감염양성솔위25.00％。량자비교차이유통계학의의（χ2=6.40，P＜0.05）；CINⅡ~Ⅲ급조：술전HPV-L1각단백양성적환자，술후12개월수방과정중，HR-HPV지속감염양성솔위2.33％；이술전HPV-L1각단백음성적환자，술후HR-HPV지속감염양성솔위22.37％。량자비교차이유통계학의의（χ2=6.44，P＜0.05）。결론 CIN환자치료전HPV-L1각단백적검측유가능성위평고CIN환자치료후예측질병전귀적지표。
Objective To investigate whether detecting human papillomavirus (HPV)-L1 capsid protein can predict the prognosis of cervical intraepithelial neoplasia (CIN) patients or not. Methods HPV-L1 capsid protein expression in pa-tient with CIN before treatment was detected through Immunocytochemical method. And then CIN patients were divided into CINⅠgroup and CINⅡ~Ⅲgroup. The expression of High-risk HPV (HR-HPV) at twelve months after treatment was detect through PCR technology. If detection of HR-HPV was positive which means HR-HPV was persistent infection. Re-sults The positive expression rate of HPV capsid protein was 75.00%in CINⅠgroup and 36.13%in CINⅡ~Ⅲgroup be-fore treatment, the difference was statistical significantly(χ2=15.43,P<0.05). Persistent infection rate of HR-HPV was 0%at 12 months after treatment in HPV-L1 capsid protein positive expression patients of CINⅠgroup and 25.00%in HPV-L1 capsid protein negative expression patients of CINⅠgroup, the difference was statistical significantly (χ2=6.40,P<0.05) . Persistent infection rate of HR-HPV was 2.33%at 12 months after treatment in HPV-L1 capsid protein positive expression patients of CINⅡ~Ⅲ group and 22.37% in HPV-L1 capsid protein negative expression patients of CINⅡ~Ⅲ group, the difference was statistical significantly (χ2=6.44,P<0.05). Conclusion HPV-L1 capsid protein can predict the prognosis of CIN patients to some extent.
